Clinical trials: Graft-vs-host Disease
Lymphocytic Leukemia, Chronic, Diffuse Large B-cell Lymphoma, Follicular Lymphoma
A Study of Obinutuzumab in Chinese Participants With CD20+ Malignant Disease
This multi-center, open-label, single-arm study will evaluate the pharmacokinetics and safety of obinutuzumab in participants with cluster of differentiation (CD) 20 positive (+) malignant disease.
- Trial name
- NCT01680991
- Testing
- Obinutuzumab
- Where
- 4 sites in China
- Volunteers
- 48 people
- Sponsor
- Hoffmann-La Roche
Graft-versus-Host Disease
Safety and Efficacy Study of Photopheresis Plus Standard Therapy to Treat Chronic Graft-versus-Host Disease
The purpose of this study is to determine whether extracorporeal photoimmune therapy with UVADEX (ECP) added to standard therapy is effective in the treatment of chronic graft-versus-host disease (GvHD).
- Trial name
- NCT00054613
- Testing
- Methoxsalen, Extracorporeal Photopheresis
- Where
- 31 sites in United States, Australia and 10 more
- Volunteers
- 72 people
- Sponsor
- Mallinckrodt
Graft Versus Host Disease
A Prospective, Open Label, Dose-escalation, SAD/MAD, Multicenter, 24weeks, Phase I/IIa Clinical Trial to Evaluate the Safety, Tolerability and Pharmacodynamics of Investigational Product (VM-001) in Patients With Graft-versus-host Disease(GvHD)
The present study is multi center, phase I/IIa clinical trial to evaluate the safety and pharmacodynamics of investigational Product (VM-001) in patients with graft-versus-host disease(GvHD).
- Trial name
- NCT05276076
- Testing
- VM-001 1X10^6 cells/kg, VM-001 3X10^6 cells/kg, VM-001 5X10^6 cells/kg
- Volunteers
- 12 people
- Sponsor
- ViGenCell Inc.
Leukemia, Myeloid, Chronic, BCR-ABL Positive
Low-dose Nilotinib and Imatinib Combination in Chronic Myeloid Leukemia Patients, With Failure, Suboptimal Response or Treatment Intolerance
The purpose of this study is to determine if low-dose imatinib and nilotinib combination, will improve treatment results in CML patients with failure, suboptimal response or intolerance to imatinib therapy.
- Trial name
- NCT01819389
- Testing
- Imatinib and Nilotinib
- Where
- Mexico
- Volunteers
- 10 people
- Sponsor
- Hospital Universitario Dr. Jose E. Gonzalez
Leukemia, Myeloid, Acute, Myelodysplastic Syndromes
Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
This study will evaluate the safety, tolerability, and efficacy of Orca-T in participants undergoing reduced intensity or non-myeloablative allogeneic hematopoietic cell transplantation (alloHCT) for hematologic malignancies.
- Conditions
- Leukemia, Myeloid, Acute, Myelodysplastic Syndromes, Mixed Phenotype Acute Leukemia
- Trial name
- NCT07216443
- Testing
- Orca-T
- Where
- 6 sites in United States
- Volunteers
- 80 people
- Sponsor
- Orca Biosystems, Inc.
Dacryocystitis; Chronic
Nasolacrimal Sac Biopsy in Endoscopic Dacryocystorhinostomy
During dacryocystorhinostomy (DCR), the lacrimal sac wall biopsy is not routinely performed, but it is recommended if there is a suspicion of underlying disease other than preoperatively or intraoperatively chronic inflammation.
- Trial name
- NCT04793230
- Testing
- biopsying
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Al-Azhar University
Acute Graft-versus-Host Disease
Universal CNK-UT Therapy for Refractory aGVHD
This is a single arm, open-label, multi-center, pilot studies (Investigator Initiated Trial, IIT) to evaluate the safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of universal T-cells engineered with chimeric…
- Trial name
- CNK-UT (NCT06750133)
- Testing
- Chimeric Natural Killer Receptor Universal T-cells (CNK-UT)
- Where
- 2 sites in China
- Volunteers
- 23 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
aGVHD, Stem Cell Transplant Complications
Low Dose Ruxolitinib in Combination With Methylprednisolone
This study is to determine the efficacy and safety of combined Low dose Ruxolitinib With Methylprednisone as Initial Therapy for the aGVHD(acute graft-versus-host disease )
- Trial name
- NCT04397367
- Testing
- Ruxolitinib 10 mg twice a day combined with Corticosteroids, Ruxolitinib 5 mg twice a day combined with Corticosteroids, Ruxolitinib 5 mg once a day combined with Corticosteroids
- Where
- China
- Volunteers
- 38 people
- Sponsor
- Chinese PLA General Hospital
Acute Graft-versus-Host Disease, Hematopoietic Stem Cell Transplantation
Tissue-resident Immune Cell Subsets in aGVHD
This is a prospective study investigating the role of tissue-resident immune cell subsets in the occurrence and progression of graft-versus-host disease following hematopoietic stem cell transplantation.
- Trial name
- NCT06708507
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Nanfang Hospital, Southern Medical University
Chronic Graft-Versus Host Disease
Treatment of Chronic GVHD of Liver or Lungs by ECP
Chronic graft-versus-host disease (GVHD) is a major complication of allogeneic hematopoietic stem cell transplantation and the leading cause of death more than 2 years after transplantation.During the past 30 years survival of…
- Trial name
- NCT00271869
- Testing
- Extracorporeal photoimmunotherapy
- Where
- Austria
- Volunteers
- 20 people
- Sponsor
- Medical University of Vienna
Spinal Cord Injury, Chronic
Intrathecal Administration of Expanded Wharton's Jelly Mesenchymal Stem Cells in Chronic Traumatic Spinal Cord Injury
This is a phase I/IIa, randomized, double-blind, two-arms, two-dose administration, placebo controlled, two-way crossover clinical trial in which 10 patients from 18 to 65 years of age affected with chronic traumatic spinal cord…
- Trial name
- NCT03003364
- Testing
- XCEL-UMC-BETA
- Where
- Spain
- Volunteers
- 10 people
- Sponsor
- Banc de Sang i Teixits
Graft-Versus-Host Disease
Allogeneic Mesenchymal Stem Cell for Graft-Versus-Host Disease Treatment
Now it is commonly accepted that MSC produce an immune-tolerant environment in different settings. It has been shown (mainly for BM-MSC) that MSC can down-regulate T cells activation.
- Trial name
- MSCGVHD (NCT00749164)
- Testing
- MSC transplantation
- Where
- Israel
- Volunteers
- 20 people
- Sponsor
- Hadassah Medical Organization
Graft Versus Host Disease
Lactobacillus Rhamnosus GG in Reducing Incidence of Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant
This randomized pilot clinical trial studies Lactobacillus rhamnosus GG in reducing incidence of graft-versus-host disease in patients who have undergone donor stem cell transplant.
- Trial name
- NCT02144701
- Testing
- Lactobacillus rhamnosus GG, laboratory biomarker analysis was not performed because of no differences in the clinical outcomes
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Rutgers, The State University of New Jersey
Leukemia, Multiple Myeloma
MSC and Cyclophosphamide for Acute Graft-Versus-Host Disease (aGVHD) Prophylaxis
Evaluating the effectiveness of the new protocol which replace the standard immunosuppressive therapy with use of MSCs and CY in patients at high risk of relapse.
- Trial name
- MSC-CY (NCT02270307)
- Testing
- Cyclophosphamide, Mesenchymal stromal cells
- Where
- Russia
- Volunteers
- 40 people
- Sponsor
- National Research Center for Hematology, Russia
Leukemia, Myelogenous, Chronic, Breakpoint Cluster Region-Abelson Proto-oncogene (BCR-ABL) Positive
A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia
Phase 3, 2-arm, randomized, open label trial. Patients will be randomized to receive bosutinib or imatinib for the duration of the study.
- Trial name
- NCT02130557
- Testing
- Bosutinib, Imatinib
- Where
- 189 sites in United States, Australia and 24 more
- Volunteers
- 536 people
- Sponsor
- Pfizer
Donor Lymphocyte Infusion, Allogeneic Hematopoietic Stem Cell Transplantation
Chemotherapy and DLI for Prevention of Second Relapse in Patients With Relapsed Acute Leukemia After Allotransplant
Patients with acute leukemia relapsing after allotransplant and who respond to anti-leukaemia interventions are at high-risk of a second relapse.
- Conditions
- Donor Lymphocyte Infusion, Allogeneic Hematopoietic Stem Cell Transplantation, Acute Leukemia, Minimal Residual Disease
- Trial name
- NCT03297528
- Testing
- donor lymphocyte infusion
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Peking University People's Hospital
Chronic Rhinosinusitis
Canadian Health Economics, Outcome, and Effectiveness Comparison of Treatment in Patients With Chronic Rhinosinusitis
The economic, patient related outcome, and effectiveness of balloon sinuplasty in the treatment of CRS patients with frontal and other sinus disease in the Canadian healthcare environment is not known at this time.
- Trial name
- CHEC (NCT01455948)
- Testing
- Relieva Balloon Sinuplasty™ System, Functional Endoscopic Sinus Surgery
- Where
- 8 sites in Canada
- Volunteers
- 25 people
- Sponsor
- Integra LifeSciences Corporation
EBV-T/NK LPD
Improved Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation Protocol for the Treatment of Epstein Barr Virus T/NK Lymphoproliferative Disease (EBV-T/NK LPD) and Prevention of Post Transplant Graft-versus-host Disease
To investigate whether the addition of recombinant humanized anti-CD25 monoclonal antibody to the conventional EBV-T/NK LPD conditioning regimen can prevent acute and chronic GVHD after transplantation, improve the severity of…
- Trial name
- NCT07029958
- Testing
- recombinant humanized anti-CD25 monoclonal antibody
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Beijing Children's Hospital
Tourette's Disorder, Persistent (Chronic) Motor or Vocal Tic Disorder
Internet-based Behaviour Therapy for Tourette's Disorder and Chronic Tic Disorder
The purpose of this study is to evaluate the feasibility and acceptability of two different modalities of therapist-guided Internet-delivered behaviour therapy (IBT) for children and adolescents (7-17 years) with Tourette's…
- Trial name
- NCT02864589
- Testing
- Internet-delivered habit reversal training, Internet-delivered exposure and response prevention
- Where
- Sweden
- Volunteers
- 23 people
- Sponsor
- Karolinska Institutet
Stroke, Chronic
Effects of Dualsite Anodic tDCS on Lower Limbs Function in Patients After Stroke: Randomized, Double-blind, Placebo-controlled, Crossover Trial
It is currently known that Transcranial Direct Current Stimulation (tDCS) can modulate cortical activity, being considered an important resource in the treatment of sequelae resulting from stroke.
- Trial name
- NCT04850963
- Testing
- Transcranial direct current stimulation (Anodal tDCS) + dual-task training, Transcranial direct current stimulation (tDCS dualsite) + dual-task traning
- Where
- Brazil
- Volunteers
- 40 people
- Sponsor
- Federal University of Paraíba
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.